Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors for Neuroprotection in Acute Ischemic Stroke
NCT07105917Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin and empagliflozin in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Distribution of mRS scores at 3 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07105917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105917.